Bortezomib is under clinical development by Millennium Pharmaceuticals and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Bortezomib’s likelihood of approval (LoA) and phase transition for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) took place on 28 Nov 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

In addition, the same event on 28 Nov 2022 increased Bortezomib’s LoA and PTSR for Graft Versus Host Disease (GVHD), increased LoA and PTSR for Myelodysplastic Syndrome, increased PTSR for Plasma Cell Neoplasm, and increased LoA and PTSR for Refractory Multiple Myeloma.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Bortezomib Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Bortezomib overview

Bortezomib (Velcade) is a dipeptide boronic acid analogue with anti-neoplastic activity. It is formulated as lyophilized powder for solution for intravenous or subcutaneous route of administration. Velcade is indicated for the treatment of multiple myeloma. The drug candidate is under development for the treatment of non-small cell lung cancer, diffuse large B-cell lymphoma, graft versus host disease, relapsed or refractory acute myelogenous leukemia, primary plasma cell leukemia, acute lymphoblastic leukemia and myelodysplastic syndrome. The drug candidate was also under development for the treatment of B-cell lymphomas including marginal zone B-cell lymphoma, nodal marginal zone B-cell lymphoma, extranodal marginal zone B-cell lymphoma, splenic marginal zone B-cell lymphoma and follicular lymphoma, as first line therapy for non-cutaneous peripheral T-cell lymphoma, including human T-cell lymphotropic virus type 1 (HTLV-1) related T-cell lymphoma, and natural killer (NK)-cell lymphoma, epithelial ovarian cancer, primary peritoneal cancer and fallopian tube cancer, relapsed/refractory light chain amyloidosis, metastatic colorectal carcinoma, follicular non-Hodgkin lymphoma, peripheral T-cell lymphoma, cutaneous T-cell lymphoma, metastatic ductal adenocarcinoma of the pancreas, bronchioloalveolar carcinoma, metastatic breast cancer, myasthenia gravis, systemic lupus erythematosus, rheumatoid arthritis, Waldenstrom macroglobulinemia and adenocarcinoma with bronchioloalveolar features.

Millennium Pharmaceuticals overview

Millennium Pharmaceuticals is a biopharmaceutical company that offers cancer therapy for the treatment of patients with multiple myeloma and relapsed mantle cell lymphoma. It is headquartered in Cambridge, Massachusetts, the US.

Quick View Bortezomib LOA Data

Report Segments
  • Innovator (NME)
Drug Name
  • Bortezomib
Administration Pathway
  • Intravenous
  • Subcutaneous
Therapeutic Areas
  • Immunology
  • Metabolic Disorders
  • Oncology
Key Developers
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.